Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2012 Apr 24;125(16):1964-6.
doi: 10.1161/CIRCULATIONAHA.112.100628. Epub 2012 Mar 19.

Warfarin pharmacogenetics: a rising tide for its clinical value

Julie A Johnson
Editorial

Warfarin pharmacogenetics: a rising tide for its clinical value

Julie A Johnson. Circulation. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr. Johnson is a leader of the International Warfarin Pharmacogenetics Consortium and is a member of the Executive Committee and site PI for the NIH COAG trial.

Comment on

References

    1. Garcia DA, Lopes RD, Hylek EM. New-onset atrial fibrillation and warfarin initiation: High risk periods and implications for new antithrombotic drugs. Thromb Haemost. 2010;104:1099–1105. - PubMed
    1. FDA drug safety communication: Safety review of post-market reports of serious bleeding events with the anticoagulant pradaxa (dabigatran etexilate mesylate) 2011 Dec 7; http://www.fda.gov/Drugs/DrugSafety/ucm282724.htm.
    1. Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, Anderson JL, Kimmel SE, Lee MT, Pirmohamed M, Wadelius M, Klein TE, Altman RB. Clinical pharmacogenetics implementation consortium guidelines for cyp2c9 and vkorc1 genotypes and warfarin dosing. Clin Pharmacol Ther. 2011;90:625–629. - PMC - PubMed
    1. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, Aquilante CL, Grosso L, Marsh S, Langaee T, Farnett LE, Voora D, Veenstra DL, Glynn RJ, Barrett A, McLeod HL. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008;84:326–331. - PMC - PubMed
    1. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360:753–764. - PMC - PubMed